GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Sponsor
University of Copenhagen
Study ID
NCT02082496
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. Furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research. The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of GLP-1 on food intake and appetite regulation in this group.

Key Dates

Start date
Jun 30, 2014
Status verified
May 2020
Primary completion
Apr 30, 2016
Completion
Apr 30, 2019

Study Design

Enrollment
50 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Control Group
    4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
  • Experimental: Case Group
    4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection

Primary Outcome Measure

Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls [ Time Frame: 4 months intervention ]

Related Studies